Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier M-A, Angermund R, Facon T. Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica 2013; 98(8):1264-1272; https://doi.org/10.3324/haematol.2013.084376.